Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13207MR)

This product GTTS-WQ13207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hyperlipidemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13207MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7390MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ6021MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ8053MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ4183MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ14544MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ6719MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ14138MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW